MedTrace Logo

Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

NCT05389046 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2024-01-17

No results posted yet for this study

Summary

This study is a multicenter clinical research and focuses on the exploring of optimal diagnosis and treatment strategies of MDD based on anhedonia.

Conditions

  • Outpatients / Inpatients With Depression

Interventions

DRUG

Escitalopram

Escitalopram

DRUG

Escitalopram+Aripiprazole

Escitalopram+Aripiprazole

DRUG

Escitalopram+omega-3 PUFAs

Escitalopram+omega-3 PUFAs

DRUG

Escitalopram+Aripiprazole+omega-3 PUFAs

Escitalopram+Aripiprazole+omega-3 PUFAs

Sponsors & Collaborators

  • Peking University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-15
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05389046 on ClinicalTrials.gov